Muna Therapeutics Announces CEO Transition and Strategic Focus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 51 minutes ago
0mins
Source: Newsfilter
- Leadership Change: Muna Therapeutics' founder, Dr. Rita Balice-Gordon, will step down as CEO to join the Board, with former iTeos Therapeutics CEO Dr. Michel Detheux taking over on June 29, 2026, which is expected to enhance the company's focus on neurodegenerative diseases.
- Clinical Advancement: Under Balice-Gordon's leadership, Muna has evolved into a clinical-stage company, with its lead asset MNA-001, a small-molecule TREM2 agonist, on track to enter Phase 2 trials for early Alzheimer's patients in early 2027, indicating strong market potential.
- Strategic Partnerships and Funding: Detheux brings over 30 years of biotech leadership experience, having raised over $1.2 billion for iTeos and established a $2 billion collaboration with GSK, which is anticipated to provide Muna with additional resources and partnership opportunities.
- Innovative Scientific Platform: Muna's MiND-MAP discovery platform published research in Nature Medicine, revealing critical roles of microglial cells in Alzheimer's, further solidifying the company's innovative position in the neurodegenerative disease treatment landscape.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
